Intertumor heterogeneity in 60 pancreatic neuroendocrine tumors associated with multiple endocrine neoplasia type 1.
Intertumor heterogeneity
MEN-1
Multiple endocrine neoplasia
NET
Pancreatic neuroendocrine tumors
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
22 02 2019
22 02 2019
Historique:
received:
17
08
2018
accepted:
17
02
2019
entrez:
24
2
2019
pubmed:
24
2
2019
medline:
20
4
2019
Statut:
epublish
Résumé
Patients with multiple endocrine neoplasia type 1 (MEN-1) develop multiple pancreatic neuroendocrine neoplasias (PNENs). Size at diagnosis and growth during follow-up are crucial parameters. According to the WHO 2017, grading is another important parameter. The impact of grading compared to size (WHO 2000) on the clinical course needs to be evaluated. Sixty PNENs of six patients with MEN-1 were retrospectively evaluated. Fifty-one tumors with a diameter of < 20 mm were graded as G1. Two of 9 tumors with diameters of ≥20 mm were graded as G2. Tumor size of ≥20 mm correlated significantly with higher proliferation (p = 0.000617). Lymph node metastases were documented in two patients with a total of 19 tumors. In one patient, all 13 tumors (diameter: 0.4 to 100 mm) were classified as G1. However, metastases were documented in 9/29 lymph nodes. In the other patient, 5 tumors (3.5 to 20 mm) were classified as G1. The sixth tumor (30 mm) was classified as G2 (Ki-67: 8%). Metastases were revealed in 2/20 lymph nodes. Tumor size of ≥20 mm seems to correlate with more aggressive MEN-1 related pancreatic disease, regardless of individual proliferation. Tumors ≥20 mm and tumors graded as G2 should be treated surgically regardless of their size.
Sections du résumé
BACKGROUND
Patients with multiple endocrine neoplasia type 1 (MEN-1) develop multiple pancreatic neuroendocrine neoplasias (PNENs). Size at diagnosis and growth during follow-up are crucial parameters. According to the WHO 2017, grading is another important parameter. The impact of grading compared to size (WHO 2000) on the clinical course needs to be evaluated.
METHODS
Sixty PNENs of six patients with MEN-1 were retrospectively evaluated.
RESULTS
Fifty-one tumors with a diameter of < 20 mm were graded as G1. Two of 9 tumors with diameters of ≥20 mm were graded as G2. Tumor size of ≥20 mm correlated significantly with higher proliferation (p = 0.000617). Lymph node metastases were documented in two patients with a total of 19 tumors. In one patient, all 13 tumors (diameter: 0.4 to 100 mm) were classified as G1. However, metastases were documented in 9/29 lymph nodes. In the other patient, 5 tumors (3.5 to 20 mm) were classified as G1. The sixth tumor (30 mm) was classified as G2 (Ki-67: 8%). Metastases were revealed in 2/20 lymph nodes.
CONCLUSIONS
Tumor size of ≥20 mm seems to correlate with more aggressive MEN-1 related pancreatic disease, regardless of individual proliferation. Tumors ≥20 mm and tumors graded as G2 should be treated surgically regardless of their size.
Identifiants
pubmed: 30795813
doi: 10.1186/s13023-019-1034-4
pii: 10.1186/s13023-019-1034-4
pmc: PMC6387504
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Références
Best Pract Res Clin Endocrinol Metab. 2001 Jun;15(2):213-23
pubmed: 11472035
JOP. 2001 May;2(3):98-104
pubmed: 11870331
Langenbecks Arch Surg. 2002 Mar;386(8):558-69
pubmed: 11914931
J Intern Med. 2003 Jun;253(6):590-8
pubmed: 12755954
Am J Med. 1958 Sep;25(3):374-80
pubmed: 13571250
Ann N Y Acad Sci. 2004 Apr;1014:13-27
pubmed: 15153416
World J Surg. 2006 May;30(5):643-53
pubmed: 16680581
Am J Surg Pathol. 2006 May;30(5):560-74
pubmed: 16699310
Virchows Arch. 2006 Oct;449(4):395-401
pubmed: 16967267
J Clin Endocrinol Metab. 2007 Mar;92(3):1118-28
pubmed: 17179192
Virchows Arch. 2007 Aug;451 Suppl 1:S9-27
pubmed: 17684761
Surgery. 2009 Oct;146(4):801-6; discussion 807-8
pubmed: 19789041
Scand J Gastroenterol. 2010 Jun;45(6):732-8
pubmed: 20205504
Virchows Arch. 2010 Jun;456(6):595-7
pubmed: 20422210
World J Surg. 2012 Jun;36(6):1375-81
pubmed: 22382771
J Natl Cancer Inst. 2012 May 16;104(10):764-77
pubmed: 22525418
JOP. 2012 Jul 10;13(4):402-8
pubmed: 22797396
Cytopathology. 2014 Dec;25(6):389-95
pubmed: 24750272
Neuroendocrinology. 2016;103(6):779-86
pubmed: 26731608
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Adv Med Sci. 2016 Mar;61(1):147-53
pubmed: 26774266
World J Surg. 2016 Jul;40(7):1729-36
pubmed: 26956903
Ann Surg. 2018 Jul;268(1):158-164
pubmed: 28263205
J Intern Med. 1998 Jun;243(6):495-500
pubmed: 9681848